Please assess the completion status of the following clinical trial:

Trial Title: Activated Protein C in Acute Stroke Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of acute ischemic stroke; acute ischemic stroke is defined as the sudden onset of a measurable neurological deficit presumably attributable to focal cerebral ischemia, and otherwise not attributable to ICH or other disease process~* Symptom onset within 0-9 hours of administration of study medication Stroke onset is defined as the time of first symptoms or signs of neurologic deficit. If the onset of symptoms/signs is unwitnessed, time of onset is presumed to be the last time the patient was observed to be intact~* Neurologic deficit on examination with NIHSS of greater than 4 and less than 23~* In women of childbearing potential, a negative urine pregnancy test prior to enrollment (to be confirmed later by serum test)~* Signed informed consent by subject or authorized representative~Exclusion Criteria:~* Computed tomography scan of the brain with evidence of intracranial hemorrhage or any finding not consistent with acute ischemic stroke as cause of presenting symptoms~* CT imaging demonstrating hypodensity more than 1/3 of MCA territory or mass effect~* Neurological (other than presenting stroke) or psychiatric condition that may affect the patient's functional status or that may interfere with the patient's assessment~* Clinically relevant pre-existing neurological deficit (historical modified Rankin score greater than 2 regardless of cause)~* Treatment with tissue plasminogen activator or other thrombolytic agent within 3 months, including treatment with tissue plasminogen activator for current stroke~* Need for treatment with anti-platelet agent or anticoagulant within 36 hours~* Previous stroke or serious head trauma within 3 months~* Major surgery within previous 14 days~* History of intracranial hemorrhage~* Rapidly improving or minor symptoms~* Symptoms suggestive of subarachnoid hemorrhage~* Gastrointestinal hemorrhage or urinary tract hemorrhage within previous 21 days~* Arterial puncture at noncompressible site within the previous 7 days~* Seizure at onset of stroke~* Use of oral anticoagulant medications at time of symptom onset or treatment with subcutaneous or intravenous heparin within previous 48 hours with elevated partial thromboplastin time~* INR values greater than 1.5~* Platelet count less than 100,000/μL~* Glucose concentration less than 40 mg/dL or greater than 400mg/dL~* Participation in another clinical trial within the last 30 days, or planned participation in another clinical trial~* Women who are currently breast-feeding~* Known resistance to activated Protein C (Factor V Leiden mutation)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tier One (Type: EXPERIMENTAL): Participants will receive APC by intravenous injection, receiving 50% of dose as a bolus and the remainder as an infusion over one ho.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues